Assert-IQ vs IRNF App

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott

IRNF App

by Apple

AI Verdict

Assert-IQ is an implantable cardiac monitor designed for long-term, continuous clinical diagnosis and management of various arrhythmias by healthcare professionals. In contrast, the IRNF App is a software feature on Apple Watch and iPhone that provides over-the-counter irregular heart rhythm notifications suggestive of AFib to individual users. While both detect heart rhythm abnormalities, Assert-IQ offers a comprehensive, physician-managed diagnostic solution, whereas the IRNF App serves as a user-facing screening tool.

Choose Assert-IQ if…

Choose Assert-IQ if your healthcare system requires a robust, long-term, and clinically managed solution for diagnosing and monitoring patients with suspected complex or infrequent heart rhythm disorders. This system provides continuous cardiac monitoring for up to six years, offering advanced arrhythmia detection and proactive clinician alerts for comprehensive patient management.

View Assert-IQ →

Choose IRNF App if…

Choose the IRNF App if you are an individual seeking a convenient, over-the-counter mobile solution to passively screen for irregular heart rhythms suggestive of Atrial Fibrillation using your Apple Watch. This free feature provides notifications and integrates with Apple Health, empowering users with initial insights to discuss with their physician.

View IRNF App →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	IRNF App
Deployment	Subcutaneously implanted device with mobile app connectivity	Unknown
FDA Status	Cleared AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

IRNF App

Tool B, the IRNF App, is a software-only feature integrated into familiar consumer devices (Apple Watch/iPhone) with intuitive user interfaces and educational materials. This makes it highly accessible and easy for the general public to use directly without medical intervention. Tool A, Assert-IQ, involves a minimally invasive procedure and is primarily managed by clinicians, with its usability focused on clinical workflows rather than direct patient interaction with the device's interface.

Clinical Value

Assert-IQ

Assert-IQ (Tool A) provides long-term, continuous cardiac monitoring for up to 6 years, with advanced arrhythmia detection algorithms and proactive clinician alerts, offering comprehensive diagnostic and management capabilities for a wide range of heart rhythm disorders. The IRNF App (Tool B) is valuable for detecting irregular rhythms suggestive of AFib and notifying users, but its scope is narrower compared to Tool A's comprehensive and continuous monitoring for various arrhythmias.

Pricing & Value

IRNF App

The IRNF App (Tool B) is free, included as a feature with compatible Apple Watch and iPhone models, offering significant value at no additional cost to the end-user. Assert-IQ (Tool A) requires enterprise-level institutional purchase, with pricing available upon contact, indicating a substantial investment for healthcare providers.

Enterprise Readiness

Assert-IQ

Assert-IQ (Tool A) is explicitly designed for large health systems, hospitals, and cardiology clinics, offering HIPAA compliance and data export capabilities, making it suitable for integration into clinical workflows. The IRNF App (Tool B), while from a large company, is a consumer-facing feature without explicit enterprise features like a Business Associate Agreement (BAA) or direct EHR integration, limiting its readiness for formal enterprise healthcare deployment.

Innovation

IRNF App

The IRNF App (Tool B) represents a significant innovation by democratizing FDA-cleared AFib screening through a software-only application on ubiquitous consumer wearables, making medical-grade detection widely accessible over-the-counter. Assert-IQ (Tool A) offers advanced features within the established field of insertable cardiac monitors, but Tool B's approach to mass-market, passive screening is arguably more disruptive and broadly impactful.

Support & Docs

Assert-IQ

As a product from Abbott Medical, Assert-IQ (Tool A) is expected to have robust institutional support, comprehensive clinical documentation, and dedicated training for healthcare professionals, which is crucial for enterprise adoption. While Apple provides user-focused onboarding and educational materials for the IRNF App (Tool B), it likely does not offer the same level of specialized clinical or IT support required by healthcare enterprises.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	IRNF App
Name	Assert-IQ	IRNF App
Company	Abbott Medical	Apple
Description	The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders.	The Apple Irregular Rhythm Notification Feature (IRNF) is an FDA-cleared software-only mobile medical application for Apple Watch and iPhone that detects irregular heart rhythms suggestive of Atrial Fibrillation (AFib) and notifies users.
Mobile App	none	Not specified
Key Features	Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetoothu00ae Low Energy data transmission, Secure cloud-based data platform, Remote monitoring capabilities, Proactive clinician alerts, Patient activator for symptom logging, Minimally invasive insertion	Irregular heart rhythm detection, Atrial Fibrillation (AFib) notification, Pulse rate data analysis using Apple Watch PPG sensor, Integration with Apple Health app for data storage and management, Onboarding and educational materials for users, History of AFib notifications, Over-the-counter (OTC) use, Utilizes machine learning for rhythm classification

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and IRNF App.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools differ in their intended clinical use and impact on a physician's diagnostic workflow for arrhythmia management?

Assert-IQ is a long-term, continuous insertable cardiac monitor designed for physician-initiated diagnosis and management of various arrhythmias, including AFib, in patients with suspected heart rhythm disorders. It provides advanced arrhythmia detection and AI-driven insights to optimize patient management and reduce false positives, integrating into a comprehensive cardiology workflow. In contrast, the IRNF App is an over-the-counter screening tool that notifies users of irregular heart rhythms suggestive of AFib, primarily for individuals not previously diagnosed with the condition, prompting them to consult a physician for further evaluation rather than providing a definitive diagnosis or treatment.

What are the capabilities for integrating data from each tool into existing Electronic Health Record (EHR) systems, and how does this affect data review and management for the physician?

Assert-IQ utilizes a secure cloud-based data platform, the Merlin.net Patient Care Network, which supports remote monitoring and programming, implying a system designed for clinical data management and potential integration with EHRs for efficient data review. The IRNF App integrates with the Apple Health app, from which patients can choose to share their health data with providers; some EHR vendors like MEDITECH, Epic, Cerner, and athenahealth support this integration via SMART on FHIR, allowing physicians to access shared data within their workflow or copy relevant information into the patient chart.

What is the reported accuracy and sensitivity of each tool for detecting relevant cardiac events, and what are the clinical implications of these performance characteristics for diagnosis and patient care?

Assert-IQ demonstrates high accuracy, with reported 99.4% episode-based AF sensitivity and 100% patient sensitivity for AF, and its AI algorithms significantly reduce false positives while maintaining high sensitivity, providing clear electrograms and IQ Insights for data-driven clinical decisions. The IRNF App's irregular rhythm notification feature has shown varying sensitivity (e.g., 21.4% to 60% for AF episodes) but high specificity (e.g., 95.5% positive predictive value by episode), serving as a screening tool that often leads physicians to recommend further diagnostic workup due to its limitations in definitive diagnosis.

What is the expected learning curve for physicians and their staff to effectively utilize each system, and what level of ongoing support is provided by the respective companies?

For Assert-IQ, the learning curve involves understanding the minimally invasive insertion procedure and navigating the Merlin.net Patient Care Network for data review and remote device programming, with Abbott providing clinician manuals, help guides, and dedicated SyncUP Remote Monitoring Support for patient setup and compliance. For the IRNF App, the physician's learning curve centers on interpreting patient-reported notifications and integrating this consumer-generated data into clinical decision-making, as there is a recognized need for uniform clinical practice guidelines regarding these alerts, and Apple primarily offers user-facing support and educational materials.

Beyond standard compliance, what specific security measures are in place for patient data with each tool, and what audit-trail features are available for clinical review and accountability?

Assert-IQ's secure cloud-based data platform (Merlin.net PCN) is stated to have stringent security certifications, and remote programming requires a two-factor authentication process for authorized personnel, with successful changes appearing in recent transmissions to imply auditability. For the IRNF App, health data is encrypted at rest on the iPhone (protected by passcode/biometrics) and in transit, utilizing a Secure Enclave, and if synced with iCloud, it can be end-to-end encrypted with two-factor authentication, with audit trails for physician actions on shared data being more dependent on the integrated EHR system.

In what specific clinical scenarios or patient populations would each tool be most appropriate, considering their distinct functionalities?

Assert-IQ is most appropriate for patients requiring long-term, continuous cardiac monitoring for diagnostic evaluation and management of suspected heart rhythm disorders, unexplained symptoms like syncope or palpitations, or those at risk for conditions such as AFib and cryptogenic stroke. The IRNF App is best suited as a proactive screening tool for individuals aged 22 and over who have not been previously diagnosed with AFib, empowering them to monitor for irregular rhythms and seek medical consultation for potential early detection.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Assert-IQ or IRNF App

Backers

Who funded each tool's parent company.

IRNF App

Transformer VC